

Redeye Initiates Coverage of Initiator Pharma

Redeye initiates coverage of Initiator Pharma, a Danish biotech company, primarily developing CNS-targeted drugs for Erectile Dysfunction (ED). The three exciting compounds in its clinical pipeline offer a compelling case, bolstered by strong management, a newly secured financial runway, and a unique niche.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Redeye Initiates Coverage of Initiator Pharma